Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dec 23, 2010 (rev. 1)


Celera this week said it has appointed Alfred Merriweather as senior vice president and CFO.

Merriweather previously was executive vice president and CFO at Calypso Medical Technologies. Prior to that, he served as CFO of Monogram Biosciences and its predecessor Aclara Biosciences, until the company was acquired by Laboratory Corporation of America in 2009.

Merriweather has also served as CFO of Symphonix Devices, Lipomatrix, and Laserscope. He also spent several years at Price Waterhouse in London and San Jose, Calif., and holds a BA in economics and MA from the University of Cambridge.

TcLand Expression recently announced the appointment of Peter Payne as its chief business officer and head of US operations.

Prior to this, Payne worked for Quintiles Transnational, where he held various positions managing senior operations and business development in Europe and the US. Most recently, he was VP of corporate development at Quintiles, and was responsible for inking strategic relationships with drug firms, venture capital funds, and other financial institutions.

TcLand Expression is developing personalized medicine companion diagnostics in immune mediated disorders and is clinically validating personalized medicine biomarkers for tolerance in liver transplantation.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more